Sichuan Hebang Biotechnology (SHSE:603077) Shareholders Have Lost 21% Over 1 Year, Earnings Decline Likely the Culprit

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Investors i

Simply Wall StMay 13 17:35

Hebang Biotech (603077.SH): Methionine project running at full capacity

Gelonghui, May 10, 丨 Hebang Biotech (603077.SH) said on the investor interactive platform that the company's methionine project is running at full capacity, and the company's methionine customers have covered well-known domestic agricultural and animal husbandry enterprises such as Muyuan Co., Ltd., New Hope, Haida Group, Shengnong Co., Ltd.; the company will create more profits for the company through continuous process optimization and sales strategy adjustments.

Gelonghui FinanceMay 10 03:26

Hebang Biotech (603077.SH): Has repurchased a total of 114.902 million shares

Gelonghui, May 7, 丨 Hebang Biotech (603077.SH) announced that as of April 30, 2024, the company had repurchased a total of 11,490,200 shares through the Shanghai Stock Exchange system, accounting for 0.13% of the company's total share capital. The highest purchase price was 2.13 yuan/share, the lowest price was 1.98 yuan/share, and the total amount paid was 23,484,329.85 yuan.

Gelonghui FinanceMay 7 02:58

Express News | Hebang Biotech: Plans to repurchase shares for 100 million yuan to 200 million yuan

BreakingsApr 24 05:37

Changes in A-shares | Hebang Biotech's net profit fell 92% year-on-year in the first quarter

Gelonghui April 22 | Hebang Biotech (603077.SH) fell to a halt, reaching a new low of 2.13 yuan since August 2021, with a market value of 18.9 billion yuan. According to news, the company achieved operating income of 1,999 billion yuan in the first quarter, a year-on-year decrease of 16.51%, and realized net profit of 29.79 million yuan, a year-on-year decrease of 92.49%. Net cash flow from operating activities was 433 million yuan, which turned negative year-on-year. The balance ratio was 23.26%, up 7.17 percentage points from the previous year.

Gelonghui FinanceApr 22 01:23

Hebang Biotech (603077.SH) announced its 2023 annual results, with net profit of 1,283 billion yuan, a year-on-year decrease of 66.29%

Hebang Biotech (603077.SH) disclosed its 2023 annual report, and the company achieved 88 revenue in 2023...

Zhitong FinanceApr 19 03:57